The federal appropriations bill includes a provision allowing Medicare coverage for multi‑cancer early detection (MCED) tests that have received FDA approval, bypassing the usual USPSTF endorsement requirement. Reimbursement will be pegged to existing rates for multi‑target stool DNA tests and will begin in 2029 with phased eligibility for ages 50–65. Exact Sciences and other diagnostics makers praised the move as a critical expansion of market access for MCED technologies. The provision reduces a major commercial barrier for MCED developers but leaves open questions about pricing, utilization rules and long‑term evidence requirements that payers and providers will press for during implementation.